Homepage
Author:
Polaryx Therapeutics, Inc.
Posted Date:
April 15, 2026
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
Polaryx Therapeutics, Inc.
April 15, 2026
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
Polaryx Therapeutics, Inc.
April 1, 2026
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
Polaryx Therapeutics, Inc.
March 17, 2026
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
Polaryx Therapeutics, Inc.
March 12, 2026
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
Polaryx Therapeutics, Inc.
February 27, 2026
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
Polaryx Therapeutics, Inc.
February 17, 2026
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
Polaryx Therapeutics, Inc.
February 10, 2026
Polaryx Therapeutics Welcomes New Members of the Board of Directors
Polaryx Therapeutics, Inc.
February 7, 2026
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
Polaryx Therapeutics, Inc.
February 3, 2026
Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”
Polaryx Therapeutics, Inc.
February 2, 2026
1
2
Next
